...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Another question re: IPO's
1
Dec 10, 2015 09:41AM
I probably should have said preferred shares (for the royalties). Enough from me. P VLee
Share
New Message
Please login to post a reply